Helicobacter pylori infection
Conditions
Interventions
Group A: Amoxicillin (1000 mg per dose, twice daily) + Vonoprazan (20 mg per dose, once daily):Group A: Amoxicillin (1000 mg per dose, twice daily) + Vonoprazan (20 mg per dose, once daily), 14-day co
Group B: Amoxicillin (1000 mg per dose, three times daily) + Vonoprazan (20 mg per dose, once daily):Group B: Amoxicillin (1000 mg per dose, three times a day) + Vonoprazan (20 mg per dose, once dail
Sponsors
Fuzhou University Affiliated Provincial Hospital
Eligibility
Sex/Gender
All
Age
60 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1 Adult patients aged between 60 and 80 years. 2 No prior use of an amoxicillin-containing regimen for Helicobacter pylori eradication before treatment, and no intake of antibiotics, bismuth preparations, or traditional Chinese medicine within 4 weeks before treatment, or proton pump inhibitors (PPIs), H2 receptor antagonists, or similar medications within 2 weeks before treatment. 3 Diagnosis of H. pylori positivity confirmed by C13 or C14 urea breath test or rapid urease test. 4 Patients were informed and agreed to participate in the study, with complete medical records and follow-up data.
Exclusion criteria
Exclusion criteria: Patients with severe primary diseases of the heart, lungs, kidneys, liver, or hematopoietic system, or those with compromised immunity. Those with contraindications due to drug allergies. Individuals with mental illnesses or communication disorders. Patients with organic lesions such as gastrointestinal tumors or gastrointestinal bleeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Degree of clinical symptom remission;Adverse reaction; | — |
Countries
China
Contacts
Public ContactXueping Huang
Fuzhou University Affiliated Provincial Hospital
Outcome results
None listed